Xuan Gu Bao·2025-08-20 12:03Fundraising - Longpan Technology plans to raise no more than 2 billion yuan for an 110,000-ton high-performance phosphate-based cathode material project, an 85,000-ton high-performance phosphate-based cathode material project, and to supplement working capital [1] Share Buyback and Equity Transfer - Juguang Technology intends to repurchase shares worth 100 million to 150 million yuan, with a repurchase price not exceeding 50 yuan per share [2] - Dongfeng Group plans to adjust the share repurchase price from not exceeding 93 yuan per share to not exceeding 6.28 yuan per share [3] - Heng Rui Medicine plans to repurchase shares worth 1 billion to 2 billion yuan, with a repurchase price not exceeding 90.85 yuan per share [4] - Guobang Medicine's shareholders plan to transfer 6.85% of the company's shares to Zhejiang State Capital Operation Co., Ltd. for a consideration of 567 million yuan [4] External Investment and Daily Operations - Changhua Group received a designated development notice from a domestic automaker for key metal structural components, with an estimated total sales amount of approximately 190 million yuan over an 8-year project lifecycle, expected to start mass production in Q3 2026 [5] - Wantong Development's PCIe 5.0 switch chip from Shudao Technology is expected to begin bulk supply by the end of 2025 [6] - Zejing Pharmaceutical received approval for clinical trials of injectable ZG005 and hydrochloride gicaxetine tablets in combination with chemotherapy [7] - Tianwei Food is planning to issue H-shares and list on the Hong Kong Stock Exchange [8] - Silek signed a memorandum of understanding with Korea's Dongwon Systems to establish a joint venture for battery shell business cooperation in the US and Europe [8] - Baibang Technology renewed its authorized service supplier agreement with Apple [9] - Hongwei Technology received a designated notice from a leading domestic new energy vehicle company, confirming it as the supplier for the SiC MOSFET device project [9] - Baotai's Usymro (Ustinumab injection) received marketing approval from the European EMA [10] Performance Changes - Muyuan Foods reported a net profit of 10.53 billion yuan in the first half of the year, a year-on-year increase of 1169.77% [11] - Suotong Development reported a net profit of 523 million yuan in the first half of the year, a year-on-year increase of 1568.52% [12] - Weicai Technology reported a net profit of 100 million yuan in the first half of the year, a year-on-year increase of 831% [12] - Chunqiu Electronics reported a net profit of 93.3183 million yuan in the first half of the year, a year-on-year increase of 248.44% [13] - Heng Rui Medicine reported a net profit of 4.45 billion yuan in the first half of the year, a year-on-year increase of 29.67% [14]